The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis
- PMID: 28436162
- DOI: 10.1002/ajmg.a.38239
The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis
Abstract
The Annual Children's Tumor Foundation International Neurofibromatosis Meeting is the premier venue for connecting discovery, translational and clinical scientists who are focused on neurofibromatosis types 1 and 2 (NF1 and NF2) and schwannomatosis (SWN). The meeting also features rare tumors such as glioma, meningioma, sarcoma, and neuroblastoma that occur both within these syndromes and spontaneously; associated with somatic mutations in NF1, NF2, and SWN. The meeting addresses both state of the field for current clinical care as well as emerging preclinical models fueling discovery of new therapeutic targets and discovery science initiatives investigating mechanisms of tumorigenesis. Importantly, this conference is a forum for presenting work in progress and bringing together all stakeholders in the scientific community. A highlight of the conference was the involvement of scientists from the pharmaceutical industry who presented growing efforts for rare disease therapeutic development in general and specifically, in pediatric patients with rare tumor syndromes. Another highlight was the focus on new investigators who presented new data about biomarker discovery, tumor pathogenesis, and diagnostic tools for NF1, NF2, and SWN. This report summarizes the themes of the meeting and a synthesis of the scientific discoveries presented at the conference in order to make the larger research community aware of progress in the neurofibromatoses.
Keywords: neurofibromatosis type 1; neurofibromatosis type 2; pediatric tumors; rare disease; schwannomatosis; therapeutic discovery.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.Am J Med Genet A. 2014 Mar;164A(3):563-78. doi: 10.1002/ajmg.a.36312. Epub 2014 Jan 17. Am J Med Genet A. 2014. PMID: 24443315 Free PMC article.
-
Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.Neuro Oncol. 2016 May;18(5):624-38. doi: 10.1093/neuonc/nov200. Epub 2016 Feb 6. Neuro Oncol. 2016. PMID: 26851632 Free PMC article. Review.
-
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.Am J Med Genet A. 2018 May;176(5):1258-1269. doi: 10.1002/ajmg.a.38675. Am J Med Genet A. 2018. PMID: 29681099 Free PMC article.
-
From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.Am J Med Genet A. 2019 Jun;179(6):1098-1106. doi: 10.1002/ajmg.a.61112. Epub 2019 Mar 25. Am J Med Genet A. 2019. PMID: 30908866 Free PMC article.
-
Schwannomatosis: a Realm Reborn: year one.Curr Opin Oncol. 2023 Nov 1;35(6):550-557. doi: 10.1097/CCO.0000000000000994. Epub 2023 Sep 1. Curr Opin Oncol. 2023. PMID: 37820090 Review.
Cited by
-
Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.Mol Diagn Ther. 2018 Feb;22(1):25-39. doi: 10.1007/s40291-017-0299-3. Mol Diagn Ther. 2018. PMID: 28900876 Review.
-
Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem.EMBO Mol Med. 2017 Sep;9(9):1179-1182. doi: 10.15252/emmm.201708203. EMBO Mol Med. 2017. PMID: 28743783 Free PMC article.
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous